EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.12
+0.15 (+1.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.97
Open15.00
Bid0.00 x 1000
Ask0.00 x 900
Day's Range14.91 - 16.59
52 Week Range5.14 - 16.59
Volume1,536,072
Avg. Volume801,340
Market Cap1.373B
Beta (3Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.56
Trade prices are not sourced from all markets
  • Epizyme Announces Positive Interim Data on Lead Candidate
    Zacks10 hours ago

    Epizyme Announces Positive Interim Data on Lead Candidate

    Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.

  • Business Wire4 days ago

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

    The data show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in both patients with EZH2 activating mutations and those with wild-type EZH2. The data will be presented today in an oral presentation entitled “Interim update from a Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma” at the International Conference on Malignant Lymphoma (ICML) by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire de Lille, France, an investigator in the Phase 2 trial.

  • Benzinga10 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

    For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...

  • Business Wire13 days ago

    Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in an oral presentation by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire and study investigator, at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)
    Insider Monkey14 days ago

    Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)

    We can judge whether Epizyme Inc (NASDAQ:EPZM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
    Zacks20 days ago

    Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire22 days ago

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

    The data will be presented today in an oral presentation entitled “Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients with epithelioid sarcoma” at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting by Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Tumori, Milan, and an investigator in the Phase 2 clinical trial. In July 2017, Epizyme completed enrollment of 62 patients in the epithelioid sarcoma cohort of its Phase 2 trial.

  • Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
    Zacks25 days ago

    Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

    Epizyme (EPZM) submits an NDA filing for tazemetostat to the FDA with an objective to treat patients suffering metastatic epithelioid sarcoma, not eligible for curative surgery. Shares inch up.

  • Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
    American City Business Journals25 days ago

    Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

    Cambridge-based Epizyme is now awaiting FDA for approval for its epigenetics first product, tazemetostat, with plans to quickly expand its applications.

  • Business Wire26 days ago

    Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered by Epizyme and being developed for a range of cancers and treatment settings.

  • Will Epizyme to Surge Higher?
    Zacks26 days ago

    Will Epizyme to Surge Higher?

    As of late, it has definitely been a great time to be an investor Epizyme.

  • Business Wire27 days ago

    Epizyme to Present at Jefferies 2019 Healthcare Conference

    Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5, 2019 at 3:00 p.m.

  • Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
    Zacks28 days ago

    Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?

    Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.

  • Business Wirelast month

    Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June. Updated data from the fully enrolled cohort of epithelioid sarcoma patients in the company’s molecularly defined solid tumor program will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Updated data from the fully enrolled cohorts of patients with follicular lymphoma, both with and without EZH2 activating mutations, will be reported at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Epizyme: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results

    Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively

  • If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today
    Simply Wall St.2 months ago

    If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today

    It is a pleasure to report that the Epizyme, Inc. (NASDAQ:EPZM) is up 39% in the last quarter. But over the last half decade, the stock has not performed well. In fact, the share price is down 39%, which falls well short o...

  • Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?
    Zacks3 months ago

    Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire3 months ago

    Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering price of each share of Series A stock was $115.00. The aggregate gross proceeds to Epizyme from the offerings, before deducting underwriting discounts and offering expenses, are $172.50 million.

  • Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?
    Simply Wall St.4 months ago

    Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?

    Rob Bazemore has been the CEO of Epizyme, Inc. (NASDAQ:EPZM) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...

  • Business Wire4 months ago

    Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deducting underwriting discounts and offering expenses. The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.

  • Business Wire4 months ago

    Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.

  • Business Wire4 months ago

    Epizyme Announces Presentations at Upcoming March Investor Conferences

    Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March inv